Santhera Pharmaceuticals Holding AG (XSWX:SANN) Other Long Term Assets: CHF1.90 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SANN Santhera Pharmaceuticals Holding AG XSWX:SANN
38 GF Score
Price CHF15.42
GF Value CHF23.44
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG Other Long Term Assets?

Santhera Pharmaceuticals Holding AG XSWX:SANN +1.05% 38 Other Long Term Assets is CHF1.90 Mil as of Dec. 2025. GuruFocus rates XSWX:SANN with a GF Score™ of 38/100 and a GF Value™ of CHF23.44 (Possible Value Trap). The stock has 6 warning signs investors should review.

Santhera Pharmaceuticals Holding AG's other long-term assets for the quarter that ended in Dec. 2025 was CHF1.90 Mil.

Santhera Pharmaceuticals Holding AG's quarterly other long-term assets declined from Dec. 2024 (CHF5.16 Mil) to Jun. 2025 (CHF3.22 Mil) but then stayed the same from Jun. 2025 (CHF3.22 Mil) to Dec. 2025 (CHF1.90 Mil).

Santhera Pharmaceuticals Holding AG's annual other long-term assets increased from Dec. 2023 (CHF0.42 Mil) to Dec. 2024 (CHF5.16 Mil) but then declined from Dec. 2024 (CHF5.16 Mil) to Dec. 2025 (CHF1.90 Mil).

Santhera Pharmaceuticals Holding AG Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Santhera Pharmaceuticals Holding AG's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG Other Long Term Assets Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.45 0.42 5.16 1.90

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.34 5.16 3.22 1.90
XSWX:SANN
38GF Score
Santhera Pharmaceuticals Holding AG XSWX:SANN
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of CHF1.90 Mil mean?
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a Other Long Term Assets of CHF1.90 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Santhera Pharmaceuticals Holding AG and its competitors.
Is Santhera Pharmaceuticals Holding AG's Other Long Term Assets too high?
Santhera Pharmaceuticals Holding AG's current Other Long Term Assets is CHF1.90 Mil. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Other Long Term Assets compare to VRTX and REGN?
Santhera Pharmaceuticals Holding AG's Other Long Term Assets of CHF1.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. Santhera Pharmaceuticals Holding AG's current Other Long Term Assets is CHF1.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.44, compared to a current price of CHF15.42 — trading 34.2% below its estimated fair value. The current Other Long Term Assets is CHF1.90 Mil. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current Other Long Term Assets is CHF1.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of CHF15.42 is trading 34.2% below its estimated GF Value™ of CHF23.44. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.

Key valuation signals for XSWX:SANN:

  • Other Long Term Assets: CHF1.90 Mil
  • GF Value™: CHF23.44 vs. price of CHF15.42 (34.2% below fair value)
  • GF Score™: 38/100 with 6 warning signs

No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
38GF Score

Get the complete analysis for XSWX:SANN

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF15.42
Price
CHF23.44
GF Value